Objective To study the relationship between the expression of breast cancer susceptibility gene (BRCA)1 and the pathological parameters in sporadic breast cancer. Method Immunohistochemistry was used to detect the expression of BRCA1 in 42 cases of breast cancer tissues and 30 cases of breast fibroadenoma tissues and analyzed the correlation of the results with other parameters which included tumor size,tumor type,histological grade and axillary lymph nodes metastases. Results The positive expression rate of BRCA1 was 52.4% (22/42) in breast cancer patients and 85.7% (36/42) in breast fibroadenoma patients. The lower positive expression rate of BRCA1 was found in axillary lymph nodes metastases (P < 0.05). The positive expression rate in stage Ⅲ of breast cancer was lower than that in stage Ⅰ (P < 0.05 ) and was also lower than that in stage Ⅱ (P < 0.05 ), but there was no significant difference between stage Ⅰ and stage Ⅱ (P > 0.05). No significant correlation was observed among expression of BRCA1 and tumor size, tumor type (P > 0.05). Conclusions BRCA1 plays an important role in pathogenesis and development of breast cancer.BRCA1 maybe a adjuvant index for treating breast cancer and estimating prognosis.

Objective To evaluate the treatment of advanced liver cancer by intraoperative argon super cryosurgery system (ASCS) Methods A total of 24 cases suffering from advanced liver cancer were treated by ASCS during operation Nine cases were treated by ASCS only, nine by ASCS in combination with liver artery or portal vein chemotherapeutic pump, four were treated by ASCS with tumor resection and chemotherapeutic pump placement, other two cases received tumor resection together with lymph nodes′ ASCS and pump placement Results The procedure was successful in all 24 cases, complications such as bleeding of puncture aperture, thorax effusion, bile leakage and hepatic coma, were successfully managed Twenty two cases have survived 6 12 months, 17 cases for 12 17 months 9 cases for 18 24 months, 5 cases for more than 24 months Conclusion Intraoperative ASCS provides a new alternative to the treatment of advanced liver cancer with acceptable complication rates